D M Sudarshana1,2, G Nair1, J T Dwyer1, B Dewey1, S U Steele1, D J Suto1, T Wu1, B A Berkowitz3, A P Koretsky1, I C M Cortese1, D S Reich4. 1. From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland. 2. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (D.M.S.), Cleveland, Ohio. 3. Department of Ophthalmology (B.A.B.), Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, Michigan. 4. From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland daniel.reich@nih.gov.
Abstract
BACKGROUND AND PURPOSE: The manganese ion is used as an intracellular MR imaging contrast agent to study neuronal function in animal models, but it remains unclear whether manganese-enhanced MR imaging can be similarly useful in humans. Using mangafodipir (Teslascan, a chelated manganese-based contrast agent that is FDA-approved), we evaluated the dynamics of manganese enhancement of the brain and glandular structures in the rostral head and neck in healthy volunteers. MATERIALS AND METHODS: We administered mangafodipir intravenously at a rate of 1 mL/minute for a total dose of 5 μmol/kg body weight. Nine healthy adult volunteers (6 men/3 women; median age, 43 years) completed baseline history and physical examination, 3T MR imaging, and blood work. MR imaging also followed mangafodipir administration at various time points from immediate to 7 days, with delayed scans at 1-3 months. RESULTS: The choroid plexus and anterior pituitary gland enhanced within 10 minutes of infusion, with enhancement persisting up to 7 and 30 days, respectively. Exocrine (parotid, submandibular, sublingual, and lacrimal) glands also enhanced avidly as early as 1 hour postadministration, generally resolving by 1 month; 3 volunteers had residual exocrine gland enhancement, which resolved by 2 months in 1 and by 3 months in the other 2. Mangafodipir did not affect clinical parameters, laboratory values, or T1-weighted signal in the basal ganglia. CONCLUSIONS: Manganese ions released from mangafodipir successfully enable noninvasive visualization of intra- and extracranial structures that lie outside the blood-brain barrier without adverse clinical effects, setting the stage for future neuroradiologic investigation in disease.
BACKGROUND AND PURPOSE: The manganese ion is used as an intracellular MR imaging contrast agent to study neuronal function in animal models, but it remains unclear whether manganese-enhanced MR imaging can be similarly useful in humans. Using mangafodipir (Teslascan, a chelated manganese-based contrast agent that is FDA-approved), we evaluated the dynamics of manganese enhancement of the brain and glandular structures in the rostral head and neck in healthy volunteers. MATERIALS AND METHODS: We administered mangafodipir intravenously at a rate of 1 mL/minute for a total dose of 5 μmol/kg body weight. Nine healthy adult volunteers (6 men/3 women; median age, 43 years) completed baseline history and physical examination, 3T MR imaging, and blood work. MR imaging also followed mangafodipir administration at various time points from immediate to 7 days, with delayed scans at 1-3 months. RESULTS: The choroid plexus and anterior pituitary gland enhanced within 10 minutes of infusion, with enhancement persisting up to 7 and 30 days, respectively. Exocrine (parotid, submandibular, sublingual, and lacrimal) glands also enhanced avidly as early as 1 hour postadministration, generally resolving by 1 month; 3 volunteers had residual exocrine gland enhancement, which resolved by 2 months in 1 and by 3 months in the other 2. Mangafodipir did not affect clinical parameters, laboratory values, or T1-weighted signal in the basal ganglia. CONCLUSIONS: Manganese ions released from mangafodipir successfully enable noninvasive visualization of intra- and extracranial structures that lie outside the blood-brain barrier without adverse clinical effects, setting the stage for future neuroradiologic investigation in disease.
Authors: Kadharbatcha S Saleem; Jon M Pauls; Mark Augath; Torsten Trinath; Burkhard A Prause; Tsutomu Hashikawa; Nikos K Logothetis Journal: Neuron Date: 2002-05-30 Impact factor: 17.173
Authors: M Federle; J Chezmar; D L Rubin; J Weinreb; P Freeny; U P Schmiedl; J J Brown; J A Borrello; J K Lee; R C Semelka; R Mattrey; A H Dachman; S Saini; S E Harms; D G Mitchell; M W Anderson; H H Halford; W F Bennett; S W Young; M Rifkin; S B Gay; R Ballerini; P F Sherwin; R O Robison Journal: J Magn Reson Imaging Date: 2000-11 Impact factor: 4.813
Authors: Chiaki Komatsu; Yolandi van der Merwe; Lin He; Anisha Kasi; Jeffrey R Sims; Maxine R Miller; Ian A Rosner; Neil J Khatter; An-Jey A Su; Joel S Schuman; Kia M Washington; Kevin C Chan Journal: J Neurosci Methods Date: 2022-02-22 Impact factor: 2.390
Authors: D J Suto; G Nair; D M Sudarshana; S U Steele; J Dwyer; E S Beck; J Ohayon; H McFarland; A P Koretsky; I C M Cortese; D S Reich Journal: AJNR Am J Neuroradiol Date: 2020-08-06 Impact factor: 3.825
Authors: Eugene Kim; Davide Di Censo; Mattia Baraldo; Camilla Simmons; Ilaria Rosa; Karen Randall; Clive Ballard; Ben R Dickie; Steven C R Williams; Richard Killick; Diana Cash Journal: Sci Rep Date: 2021-06-14 Impact factor: 4.379
Authors: Per Jynge; Arne M Skjold; Ursula Falkmer; Rolf G G Andersson; John G Seland; Morten Bruvold; Viggo Blomlie; Willy Eidsaunet; Jan O G Karlsson Journal: Contrast Media Mol Imaging Date: 2020-09-04 Impact factor: 3.161